Hetrombopag
- Generic Name
- Hetrombopag
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22N4O5
- CAS Number
- 1257792-41-8
- Unique Ingredient Identifier
- 9WGT51BDDL
- Background
Hetrombopag is under investigation in clinical trial NCT03976882 (Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Subjects With Malignancy.).
- Associated Conditions
- -
- Associated Therapies
- -
A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Registration Number
- NCT05261646
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05088343
- Locations
- 🇨🇳
Xueying General Ding, Shanghai, Shanghai, China
Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05024877
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05018936
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 117
- Registration Number
- NCT04737850
- Locations
- 🇨🇳
Beijing children's hospital .Capital medical university, Beijing, Beijing, China
Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT04688008
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 129
- Registration Number
- NCT03976882
- Locations
- 🇨🇳
Najing Bayi Hospital, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath